DelveInsight’s “Graft versus Host Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Graft versus Host Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Graft versus Host Disease drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Graft versus Host Disease treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Graft versus Host Disease: An Overview
Graft-versus-host disease (GvHD) is an immune condition that occurs when immune cells (T cells) after transplant procedures from the donor (known as the graft or graft cells) attack the recipient patient host’s tissues (healthy cells); the disease is a side effect that is common after an allogeneic bone marrow transplant (stem Cell Transplantation).
The two main types of GvHD are acute GvHD and chronic GvHD. Other than this, GvHD is classified into other types, namely: classic acute GvHD, persistent, recurrent, late-onset acute GvHD, classic chronic GvHD, overlap syndrome, and de novo chronic GvHD. Patients who get acute GvHD have a 50% chance of developing chronic GvHD.
Acute GvHD (aGvHD) might occur once the donor’s cells have engrafted in the transplant recipient and have been observed to affect the skin, liver, or gastrointestinal tract. Symptoms might appear within 3 months after the transplant.
Graft versus Host Disease Market Key Facts
In 2020, the 7MM reported 24,049 allogeneic cases, with a CAGR projecting an increase in cases by 2030. The United States accounted for 9,857 allogeneic cases in 2020, representing the highest percentage, of all allo-HSCT in the 7MM.
GvHD is categorized into two types: aGvHD and cGvHD. In 2020, acute GvHD cases accounted for 11,638, while chronic cases accounted for 7,854. In the 7MM, the aGvHD and cGvHD cases are expected to rise to by 2030 during the forecast period, i.e., 2021–2030. Germany has the highest number of cases of GvHD by type (acute and chronic) among the EU-5 nations, with 2,984 in 2020.
In the event of GvHD, corticosteroids are the first line of treatment; however, secondary data demonstrate that up to 40%-60% of all patients will be refractory to steroids. As per DelveInsight’s analysis, around 3,278 cases of cGvHD were treated in the first-line in the United States in 2020
The mortality-adjusted treatment rate is used to estimate the number of living patients who are receiving treatment or who will be eligible for treatment. In 2020, the 7MM mortality adjusted treated aGvHD patients were 9,951 in first-line.
Major pharma giants such as CSL Behring [CSL 964 Alpha-1 antitrypsin (AAT)], Medac [obnitix (MC0518)], Equillium/Biocon [itolizumab], OncoImmune/Merck (MSD) [MK-7110 (CD24Fc)], ElsaLys Biotech/Mediolanum Farmaceutici Spa [Leukotac (inolimomab)], Xenikos [T-Guard], Mesoblast/Osiris Therapeutics [RYONCIL (remestemcel-L; prochymal)], Syndax Pharmaceutical [axatilimab (SNDX-6532)], Regimmune Corporation (RGI-2001) and several others are actively involved in the development of novel therapies.
Graft versus Host Disease Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Graft versus Host Disease pipeline therapies. It also thoroughly assesses the Graft versus Host Disease market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Graft versus Host Disease drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Graft versus Host Disease Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Graft versus Host Disease epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Graft versus Host Disease epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Graft versus Host Disease Epidemiology, Segmented as –
Total Hematopoietic stem-cell transplantation (HSCT)
Total Allogeneic Transplant cases, Total GvHD cases by Types (Acute and Chronic)
Total Incident Cases of aGvHD by Grading and Organ Involvement
Total Incident cases of cGvHD by Grading and organ involvement
Total Treated patients of GvHD and Mortality adjusted GvHD treated patients
Graft versus Host Disease Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Graft versus Host Disease market or expected to be launched during the study period. The analysis covers the Graft versus Host Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Graft versus Host Disease drugs based on their sale and market share.
The report also covers the Graft versus Host Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Graft versus Host Disease companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Graft versus Host Disease Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market
Graft versus Host Disease Therapeutics Analysis
Treatment is grounded on drugs that reduce the body’s immune response and reduce T cells’ number. The current hallmark of treatment for GvHD is Immunosuppressant medications. These include both corticosteroid drugs and more advanced medications and techniques that decrease the immune response.
Commonly used medications that are given in the management of GvHD include steroids (prednisolone; Methylprednisolone), Calcineurin inhibitors (Cyclosporine; Tacrolimus), Cyclophosphamide (Cytoxan), Antithymocyte globulins (Thymoglobuline; ATG-Grafalon), Monoclonal antibodies (Alemtuzumab; Infliximab; Rituximab; Basiliximab), Mechanistic target of Rapamycin (mTOR) inhibitor (Sirolimus; Everolimus), Tyrosine kinase inhibitors (Imatinib), Tumor necrosis factor (Etanercept), Thalidomide, Inosine monophosphate dehydrogenase (IMDH) inhibitor (mycophenolate mofetil), chemotherapy drugs (Pentostatin; Methotrexate), Janus kinase (JAK) inhibitor (Ruxolitinib; Itacitinib), Rho-associated coiled-coil kinase 2 (ROCK-2) inhibitor (belumosudil) and Bruton’s tyrosine kinase (BTK) inhibitor (Ibrutinib).
Looking at the rising need for approved and legalized treatment options, many key companies across the world are developing novel therapies that would help in combating the complications caused by GvHD, in addition to this, the developers are also trying to come up with salvage therapy or curative therapy. Currently, ElsaLys Biotech is leading the therapeutics segment, with its drug candidates in the most advanced stage of clinical development.
Graft versus Host Disease Companies Actively Working in the Therapeutics Market Include
AltruBio, Amgen, ASC Therapeutics, AstraZeneca, Biogen, Bristol-Myers Squibb, Chia Tai Tianqing Pharmaceutical Group, CSL Behring, CTI BioPharma, ElsaLys Biotech (Mediolanum Farmaceutici Spa), Equillium, GlaxoSmithKline, Glia, Incyte Corporation, Jazz Pharmaceuticals, JCR therapeutics, Kadmon Corporation, MaaT Pharma, Medac, Medsenic, Mesoblas, Millennium Pharmaceuticals/Takeda Oncology, Novartis, OncoImmune/Merck (MSD), Osiris Therapeutics, Pfizer, Plexxikon, Prevention Bio, REGiMMUNE, Regimmune Corporation, Roche-Genentech, SCM Lifescience, Syndax Pharmaceuticals, Synthetic Biologics, Takeda, VectivBio, Xenikos, Xenothera, and others.
Emerging and Marketed Graft versus Host Disease Therapies Covered in the Report Include:
AbGn-168H (Neihulizumab): AltruBio
Arscimed (arsenic trioxide): Medsenic
ASC930: ASC Therapeutics
Calquence (Acalabrutinib): AstraZeneca
CSL 964 Alpha-1 antitrypsin (AAT): CSL Behring
Efavaleukin Alfa (AMG 592): Amgen
EQ001 (Itolizumab; Bmab600): Equillium/Biocon
Itacitinib: Incyte Corporation
Jakafi (Ruxolitinib): Incyte Corporation
KD025 (Belumosudil): Kadmon Corporation
Leukotac (Inolimomab): ElsaLys Biotech (Mediolanum Farmaceutici Spa)
MaaT013: MaaT Pharma
MK-7110 (CD24Fc): OncoImmune/Merck (MSD)
Obnitix (MC0518): Medac
Pacritinib (Epjevy; ONX-0803): CTI BioPharma
RGI-2001: Regimmune Corporation
SNDX-6532 (Axatilimab; GvHD B6352): Syndax Pharmaceutical
T-Guard: Xenikos
Temcell (Ryoncil; Remestemcel-L; Prochymal): JCR therapeutics/ Mesoblast/ Osiris Therapeutics
Teplizumab: Prevention Bio
Imbruvica (Ibrutinib): Pharmacyclics (Acquired by Abbvie)/ Janssen
Ornecia (abatacept): Bristol Mayers Squibb
Rezurock (Belumosudil): Kadmon Corporation (Subsidiary of Sanofi)
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Graft versus Host Disease Competitive Intelligence Analysis
4. Graft versus Host Disease Market Overview at a Glance
5. Graft versus Host Disease Disease Background and Overview
6. Graft versus Host Disease Patient Journey
7. Graft versus Host Disease Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Graft versus Host Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Graft versus Host Disease Unmet Needs
10. Key Endpoints of Graft versus Host Disease Treatment
11. Graft versus Host Disease Marketed Therapies
12. Graft versus Host Disease Emerging Drugs and Latest Therapeutic Advances
13. Graft versus Host Disease Seven Major Market Analysis
14. Attribute Analysis
15. Graft versus Host Disease Market Outlook (In US, EU5, and Japan)
16. Graft versus Host Disease Companies Active in the Market
17. Graft versus Host Disease Access and Reimbursement Overview
18. KOL Views on the Graft versus Host Disease Market
19. Graft versus Host Disease Market Drivers
20. Graft versus Host Disease Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Acute Heart Failure Market
“Acute Heart Failure Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Acute Heart Failure market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Acute Heart Failure market.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailAddress:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/medical-devices
